GlassScriptPhysician profile
Scott Arnold Mcintyre
NPI 1528554094
$6,786.59
in general payments reported to CMS, 2019-2025
22 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $639 · 2022: $915 · 2023: $1,120 · 2024: $1,910 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,129 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,128.83 |
| Education | $104.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,472.28 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $1,302.05 | 2021-2024 | Nuplazid |
| Gilead Sciences, INC. | $913.26 | 2021-2025 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $454.73 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $369.60 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $362.35 | 2022-2025 | Entyvio |
| Ardelyx, INC. | $359.84 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.52 | 2021-2025 | Xifaxan |
| Qol Medical, LLC | $335.36 | 2024-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $186.36 | 2024-2025 | Voquezna |
| Pfizer INC. | $157.51 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $118.52 | 2023-2025 | Ocaliva |
| Redhill Biopharma INC. | $113.88 | 2021 | |
| Aimmune Therapeutics, INC. | $55.88 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $51.16 | 2024-2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $46.33 | 2024 | Zeposia |
| Amarin Pharma, INC. | $39.90 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $28.17 | 2025 | Dupixent |
| Lilly USA, LLC | $25.31 | 2024 | Omvoh |
| Celltrion USA INC. | $20.34 | 2024 | Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mcintyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.